Biocryst Pharmaceuticals has been on an uptrend as of mid-December as shown in Figure 7.5. The MACD strategy described in Chapter 3.2 was used to make a trading decision on this stock. The MACD line just crossed the zero line, indicating direction is to continue with an uptrend, so 5,100 shares were bought at $3.94 apiece, giving a total invested amount of $20,094.00. We will be monitoring this stock closely for when the MACD line falls, which will signal to sell the stock.